From 13th to 15th of October, 2015, Grindeks and its subsidiary “Kalceks” participate in the leading pharmaceutical exhibition “CPhI Worldwide 2015” in Madrid, Spain.
During the exhibition both Grindeks and “Kalceks” representatives will discuss cooperation opportunities with their business partners, while potential cooperation partners will be introduced to products and services by both companies. The joint Grindeks and “Kalceks” exhibition stand will be placed in the Hall 10 with number 10G41.
Grindeks will promote cooperation in the following business fields:
· Complicated, multi-stage synthesis of APIs;
· FDF development and manufacturing of tablets, capsules, injections and topical forms;
· Customized contract manufacturing of FDF
· Out-Licensing and sales of generic medication
· Pharmaceutical product analysis, analytical method development and validation
As Grindeks branches and representative offices are represented in 13 countries during the exhibition other pharmaceutical companies will be offered to cooperate in the sales and marketing of their products in Russia and other CIS countries. The company will also inquire in-licensing opportunities of new products and meet with its existing business partners of raw material field.
The Chairman of the Board of JSC Grindeks Juris Bundulis: “Participation in the pharmaceutical field’s leading event “CPhI Worldwide” not only let us to strengthen the cooperation with our existing partners but it also represents the company for new potential partners. While competing in the global pharmaceutical market one of the biggest Grindeks advantages is the ability to provide vertically integrated or complete manufacturing cycle from the development of the active pharmaceutical ingredient to the manufacturing of the final dosage form. ”
One of the most successful vertically integrated Grindeks products is oxytocin whose both active pharmaceutical ingredient and final dosage form – injection – are being manufactured at Grindeks. The company’s product range of vertically integrated production also includes zopiclone, imatinib and UDCA.
“Kalceks” will promote cooperation in the research, development, manufacturing, as well as sales and out-licensing of sterile generics medication.
By participating in the exhibition the company is planning to expand its business activities in new markets. “Kalceks” mainly specializes in CNS medication therapeutic group including products for anaesthesia and analgesia in hospital segment.
“CPhI Worldwide” is the world’s most important pharmaceutical exhibition, which, in 2015, is held for the 26rd time and gathers pharmaceutical product manufacturers and related industry representatives from all over the world.
The participation of Grindeks in “CPhI Worldwide 2015” is co-financed by the European Regional Development Fund.
